Login to Your Account

Point Therapeutics Starts Phase III Talabostat Push

By Randall Osborne

Monday, October 17, 2005
Less than a month after disclosing the next step of its Phase II study with talabostat for leukemia - and days after winning an FDA grant for the drug - Point Therapeutics Inc. launched the most advanced trial yet with the compound, starting its Phase III program to test talabostat in metastatic non-small-cell lung cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription